Gabapentinoids linked to increased risk for severe exacerbation in COPD
Jan 16, 2024
Compared with matched nonusers, gabapentinoid users have an increased risk across indications of epilepsy, neuropathic pain and other chronic pain.
Peripheral blood Haplo-SCT feasible for leukemia patients 70 years and older
Dec 20, 2023
Haploidentical stem cell transplantation using nonmyeloablative conditioning regimen was effective in highly selected patients.
Company seeks FDA approval for MDMA as treatment for PTSD
Dec 13, 2023
“If approved, MDMA-assisted therapy would be the first psychedelic-assisted therapy, which we hope will drive additional investment into new research in mental health.”
FDA approves new diet drug Zepbound, a version of the diabetes med Mounjaro
Nov 09, 2023
Zepbound works by activating hormone receptors in the body to reduce appetite and food intake
FDA approves Voquezna for erosive esophagitis, GERD
Nov 07, 2023
A Phase 3 trial showed noninferiority versus lansoprazole in healing and maintenance phases.
FDA approves Wezlana for multiple inflammatory diseases
Nov 02, 2023
Approval of the biosimilar allows for interchangeable use with Stelara in both adult and pediatric patients
FDA approves nivolumab as adjuvant treatment for melanoma
Oct 18, 2023
Approval was granted for patients aged 12 years and older with stage IIB/C disease.
CDC panel gives support to new COVID-19 booster shots
Sep 13, 2023
The new booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating.
FDA approval of new COVID-19 boosters could come by Friday
Sep 07, 2023
The new booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating.
FDA approves Izervay for geographic atrophy tied to age-related macular degeneration
Aug 09, 2023
Two trials show significant slowing of geographic atrophy progression at the 12-month primary end point.